NEWS ARTICLE: NEW GENERIC MEDICINE FROM LUPIN
01 Apr 2019
Lupin, the pharmaceutical company has launched its new generic medicine Levothyroxine sodium tablets approved by US Food and Drug Administration in the United States market on Friday. This product is the generic version of AbbVie Inc’s Synthroid tablets. Lupin has stated that the tablets act as supplemental therapy for hypothyroidism and as a radioiodine therapy for thyroid cancer. As per January 2019 statistics, the Levothyroxine has increased the strengths from 25 mg to 300 mg with an annual sales report of 2.5 billion US Dollars. The firm’s share trading was Rs. 749.50 in BSE.